[go: up one dir, main page]

NO20010954L - Antioksidantsammensetning som innbefatter acetyl L-karnitin og <alfa>-lipoidsyre - Google Patents

Antioksidantsammensetning som innbefatter acetyl L-karnitin og <alfa>-lipoidsyre

Info

Publication number
NO20010954L
NO20010954L NO20010954A NO20010954A NO20010954L NO 20010954 L NO20010954 L NO 20010954L NO 20010954 A NO20010954 A NO 20010954A NO 20010954 A NO20010954 A NO 20010954A NO 20010954 L NO20010954 L NO 20010954L
Authority
NO
Norway
Prior art keywords
carnitine
lipoic acid
alfa
composition including
antioxidant composition
Prior art date
Application number
NO20010954A
Other languages
English (en)
Other versions
NO20010954D0 (no
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11406116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20010954(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of NO20010954D0 publication Critical patent/NO20010954D0/no
Publication of NO20010954L publication Critical patent/NO20010954L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det vises en sammensetning som innbefatter som kjennetegnede aktive bestanddeler acetyl L-karnitin og a-lipoinsyre, for forebygging og/eller terapeutisk behandling av forskjellige forandringer og patologiske tilstander indusert av frie radikaler, som kan ta form av et kosttilskudd, koststøtte eller av et egentlig legemiddel.
NO20010954A 1998-09-01 2001-02-26 Antioksidantsammensetning som innbefatter acetyl L-karnitin og <alfa>-lipoidsyre NO20010954L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998RM000566A IT1302307B1 (it) 1998-09-01 1998-09-01 Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
PCT/IT1999/000268 WO2000011968A1 (en) 1998-09-01 1999-08-19 ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID

Publications (2)

Publication Number Publication Date
NO20010954D0 NO20010954D0 (no) 2001-02-26
NO20010954L true NO20010954L (no) 2001-04-25

Family

ID=11406116

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010954A NO20010954L (no) 1998-09-01 2001-02-26 Antioksidantsammensetning som innbefatter acetyl L-karnitin og <alfa>-lipoidsyre

Country Status (28)

Country Link
US (1) US6365622B1 (no)
EP (1) EP1112005B2 (no)
JP (1) JP4361215B2 (no)
KR (1) KR20010079699A (no)
CN (1) CN1315835A (no)
AR (1) AR022076A1 (no)
AT (1) ATE228312T1 (no)
AU (1) AU773424B2 (no)
BR (1) BR9913288A (no)
CA (1) CA2341973C (no)
CZ (1) CZ2001541A3 (no)
DE (1) DE69904208T3 (no)
DK (1) DK1112005T4 (no)
EE (1) EE200100113A (no)
ES (1) ES2188214T5 (no)
HK (1) HK1039730A1 (no)
HU (1) HU229165B1 (no)
IL (1) IL141435A0 (no)
IS (1) IS5850A (no)
IT (1) IT1302307B1 (no)
MA (1) MA25284A1 (no)
NO (1) NO20010954L (no)
PL (1) PL212737B1 (no)
PT (1) PT1112005E (no)
SK (1) SK2632001A3 (no)
TN (1) TNSN99163A1 (no)
TR (1) TR200100610T2 (no)
WO (1) WO2000011968A1 (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479069B1 (en) 1999-09-23 2002-11-12 Juvenon, Inc. Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
WO2001032168A1 (en) * 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
DE10036797A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Verwendung von Kombinationen mit einem Gehalt an Carnitinen
WO2002043666A2 (en) * 2000-10-31 2002-06-06 Colgate-Palmolive Company Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US20020076470A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
JP2010142237A (ja) * 2000-10-31 2010-07-01 Colgate Palmolive Co 組成物及び方法
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
JP2004519241A (ja) * 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 高齢化に伴う生理的障害を改善し寿命を延ばす組成物
SE0102380D0 (sv) * 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
US6923960B2 (en) * 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
MXPA04006039A (es) * 2001-12-19 2004-09-27 The Quigley Corp Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
EP1476440A4 (en) * 2002-02-22 2005-06-01 Albany College Of Pharmacy METHODS AND COMPOUNDS USEFUL IN INHIBITION BY RADICAL AND / OR OXIDIZING AGGRESSION AND IN THE TREATMENT AND PREVENTION OF DISEASE
CA2531056A1 (en) * 2002-10-11 2004-04-22 Creagri, Inc. Therapeutic combination of carnitine and antioxidant polyphenols
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
DE10258239A1 (de) * 2002-12-13 2004-06-24 Degussa Ag Formulierung enthaltend alpha-Liponsäure(-Derivate) als alleinigen Wirkstoff bei nichtchronischen alkoholinduzierten Intoxikationen
US20040265345A1 (en) * 2003-06-30 2004-12-30 Perricone Nicholas V. Treatment of skin damage using acetyl carnitine and lipoic acid
US20050214413A1 (en) * 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
US7999003B2 (en) 2003-08-26 2011-08-16 Mannatech, Incorporated Antioxidant compositions and methods thereto
CA2550625C (en) * 2003-12-31 2013-05-28 Integrative Health Consulting, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
CN101106984B (zh) * 2004-11-24 2012-10-24 希尔氏宠物营养品公司 包含硫辛酸的组合物及其用途
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
JP5785355B2 (ja) * 2004-11-24 2015-09-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における生体異物物質の肝臓クリアランスを改良する方法
AU2005322015B2 (en) 2004-12-29 2010-02-25 Hill's Pet Nutrition, Inc. Methods for inhibiting a decline in learning and/or memory in animals
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CN102907561A (zh) * 2004-12-30 2013-02-06 希尔氏宠物营养品公司 提高老年动物的生活质量的方法
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
RU2402919C2 (ru) 2005-07-14 2010-11-10 Хилл'С Пет Ньютришн, Инк. Способ продления жизни животных
US8318954B2 (en) * 2006-02-23 2012-11-27 Nou Life Sciences, Inc. Cleavable carnitine compound
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
CN101057857B (zh) * 2006-04-21 2011-05-18 中国科学院上海生命科学研究院 一种预防与改善帕金森氏症的组合物及其制法
KR100811110B1 (ko) * 2007-02-21 2008-03-06 주식회사 디피아이 솔루션스 수분산성 α-리포산 캡슐 조성물을 함유하는 어류의 면역력증강용 사료첨가제 및 그 사용방법.
US20080226696A1 (en) * 2007-03-15 2008-09-18 Ben Treadwell Methods of improving learning abilities of aged companion animals
KR20090014568A (ko) * 2007-08-06 2009-02-11 (주)바이오제닉스 코팅된 알파리포산 입자, 이를 포함하는 조성물 및 그 제조방법
US20100255109A1 (en) * 2007-08-06 2010-10-07 Biogenics, Inc. Stabilized antioxidant particles, composition comprising the same and method for preparing the same
US7943163B2 (en) 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
KR100903549B1 (ko) * 2008-07-29 2009-06-23 주식회사 카이로제닉스 균질한 결정성의 아세틸-ｌ-카르니틴과 티옥트산 칼륨염의 복합염, 이의 제조방법 및 이를 포함하는 약학적 조성물
JP2012508267A (ja) * 2008-11-11 2012-04-05 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ セルライトの処置に有用な化合物
EP2389931A1 (en) * 2010-05-21 2011-11-30 Raw Materials Internatinal LLC Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
EP2787969B1 (en) 2011-12-07 2021-09-29 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US20140371280A1 (en) * 2013-03-15 2014-12-18 Shinichi Okuyama Method of treating diabetic peripheral neuropathy through amendment of pre-neuronal diabetic coagulative micro-angiopathy and neuronal deficiency of mitochondrial ATP production, and through induction of neuronal regeneration
US20190290609A1 (en) * 2014-03-19 2019-09-26 Epitech Group S.P.A. Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
CA2965671A1 (en) 2014-10-24 2016-04-28 Robert Shorr Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
JP6768653B2 (ja) 2014-11-25 2020-10-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 安定したオメガ−３眼科用組成物
WO2016157053A1 (en) * 2015-03-31 2016-10-06 Kolinpharma S.P.A. A composition for the treatment of neuropathies and/or neuropathic pain
HUE051027T2 (hu) * 2015-08-24 2021-01-28 Vitrolife Sweden Ab Tenyésztõ tápközeg
EP3849542A1 (en) * 2018-09-10 2021-07-21 URIACH ITALY S.r.l. Composition comprising lipoic acid and vitamin d for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies
CN111467385B (zh) * 2019-01-24 2022-05-17 深圳市华大农业应用研究院 组合物在预防或治疗神经退行性疾病中的用途
CA3130389C (en) * 2019-04-18 2024-01-16 Simo Rasi Composition for use in prevention or reduction of oxidative stress and neurodegenerative diseases
WO2022215085A1 (en) * 2021-04-06 2022-10-13 Celagenex Research (India) Pvt. Ltd. A synergistic composition for potentiating stabilized atp
CN112999220B (zh) * 2021-04-07 2022-12-13 中国人民解放军南部战区总医院 α-硫辛酸在作为和/或制备金属β-内酰胺酶抑制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1997002041A1 (en) * 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US5977162A (en) 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
JP2001511153A (ja) 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress

Also Published As

Publication number Publication date
ITRM980566A0 (it) 1998-09-01
CA2341973A1 (en) 2000-03-09
US6365622B1 (en) 2002-04-02
DK1112005T3 (da) 2002-12-30
SK2632001A3 (en) 2001-08-06
JP4361215B2 (ja) 2009-11-11
DK1112005T4 (da) 2010-06-14
TR200100610T2 (tr) 2001-07-23
CZ2001541A3 (cs) 2001-09-12
DE69904208T2 (de) 2003-08-28
HUP0102909A3 (en) 2002-12-28
NO20010954D0 (no) 2001-02-26
ES2188214T3 (es) 2003-06-16
EE200100113A (et) 2002-06-17
PL346318A1 (en) 2002-01-28
JP2002523435A (ja) 2002-07-30
AU5387199A (en) 2000-03-21
CN1315835A (zh) 2001-10-03
ATE228312T1 (de) 2002-12-15
EP1112005B2 (en) 2010-03-24
CA2341973C (en) 2009-05-12
WO2000011968A8 (en) 2000-05-11
AU773424B2 (en) 2004-05-27
DE69904208D1 (de) 2003-01-09
DE69904208T3 (de) 2010-09-30
EP1112005A1 (en) 2001-07-04
WO2000011968A1 (en) 2000-03-09
TNSN99163A1 (fr) 2005-11-10
HU229165B1 (en) 2013-09-30
HUP0102909A2 (hu) 2002-03-28
PT1112005E (pt) 2003-03-31
ES2188214T5 (es) 2010-06-08
KR20010079699A (ko) 2001-08-22
MA25284A1 (fr) 2001-12-31
BR9913288A (pt) 2001-05-22
IL141435A0 (en) 2002-03-10
ITRM980566A1 (it) 2000-03-01
IT1302307B1 (it) 2000-09-05
PL212737B1 (pl) 2012-11-30
HK1039730A1 (zh) 2002-05-10
EP1112005B1 (en) 2002-11-27
IS5850A (is) 2001-02-16
AR022076A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
NO20010954L (no) Antioksidantsammensetning som innbefatter acetyl L-karnitin og &lt;alfa&gt;-lipoidsyre
ATE311874T1 (de) Kosmetische, diätetische oder pharmazeutische zusammensetzung die thioctsäure und cystein enthalten
NO20006431L (no) Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom
NO20006430L (no) Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner
WO2002062751A1 (fr) Nouveaux derives de cystine et inhibiteurs de l&#39;activation des facteurs inflammatoires
BR9814484A (pt) &#34;pró-drogas de inibidores de aspartil protease&#34;
DK0787489T3 (da) Sammensætning, der indeholder propionyl-L-carnitin og hydroxycitronsyre eller pantothensyre
EP1362846A4 (en) AMINOETHANOL DERIVATIVES
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
WO2001019776A3 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
TR200102811T2 (tr) Oral uygulama için, tolpersiyon içeren farmasötik preparat.
TR200100333T2 (tr) Bir karnitin ve bir karotenoit içeren antioksidan, antiproliferos bileşim
NO20021640L (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba
TR200003737T1 (tr) Diyet takviyesi ya da ilaç olarak kullanılan bileşim
WO2000000183A3 (en) Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin
WO2001093865A3 (de) Mittel zur therapie von demenzen
HUP0303628A2 (hu) Ketosavakból és aminosavakból képzett gyomornedválló sók, valamint azok alkalmazása gyógyszerkészítmények előállítására
DK1409449T3 (da) Alpha-ketoglutarater af aktive ingredienser og sammensætninger omfattende disse
Bolognesi et al. Synthesis of new lipoic acid conjugates and evaluation of their free radical scavenging and neuroprotective activities
NO20020917L (no) Behandling av migrene ved administrering av en &lt;alfa&gt;- liponsyre eller derivater derav
IT1307278B1 (it) Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil
DE60326262D1 (de) Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden
WO2001007039A3 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
NO20023117L (no) Sammensetning for forebygging og/eller behandling av lipidmetabolismeforstyrrelser og allergiske former

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application